The Innovative Research, Technologies and Solutions that put Wales at the Forefront of Fighting Cancer
Life Sciences Hub Wales have launched a captivating series of digital case studies spotlighting cancer innovations happening in Wales.
Featuring pioneering projects from QuicDNA and CanSense, this series demonstrates a commitment to advancing cancer care through innovative technologies and approaches.
Improving cancer outcomes in Wales is a priority. Life Sciences Hub Wales are working with health, social care, academia and industry to accelerate the development of pioneering cancer care solutions. This video series highlights the remarkable work of QuicDNA and CanSense, focusing on advancements in early detection and targeted treatments. These innovations have the potential to save lives, improve patient outcomes, and reduce strain on healthcare systems.
Reducing the time to access treatment
QuicDNA: This project involves cross-sector partners and funders to ensure the widespread reach and impact of liquid biopsy technology. A liquid biopsy is a simple and non-invasive alternative to surgical tumour biopsies done through a blood test or can be used to complement tumour biopsy to shorten the time to treatment. The video also features insights from Craig Maxwell (also pictured above), discussing the impact of this project, and the importance of ongoing fundraising efforts.
“I think Craig has been absolutely quite unique in this. He’s taken the opportunity, albeit with an advanced diagnosis of cancer, to say what can he do to improve both the system and improve outcomes for patients coming after him. Which is quite inspirational for the rest of us. He’s inspiring us to work more effectively across Wales.” Professor Tom Crosby, Cancer Clinical Director for Wales.
Non-Invasive Diagnosis of Bowel Cancer Using AI-driven models
CanSense is a med-tech startup focused on developing a blood-based assay for the non-invasive diagnosis of bowel cancer using AI-driven models. Colorectal cancer, also known as bowel cancer, ranks as the third most common cancer globally, accounting for approximately 10% of all cancer diagnoses and the second leading cause of cancer-related deaths worldwide.
“Patients understand the CanSense blood test: it’s simple, acceptable and strongly preferred over unnecessary colonoscopies. The ability of the test to detect the earliest signs of cancer is incredibly exciting. What CanSense is doing is really changing the landscape of how we detect cancer for good. It’s a really exciting place to be at the moment.” Professor Dean Harris, Clinical Directory of CanSense.
Cancer can prevent people from living healthier and longer lives and increase pressures on the health and social care system. By driving life science innovation to the frontline of care, we can help improve these outcomes.
“Cancer care in Wales is advancing, but challenges remain. By showcasing innovations like QuicDNA and CanSense, we aim to inspire and show how innovative technologies can transform cancer detection and treatment. Partnerships across health, social care, and industry are vital. We foster collaboration to accelerate the deployment of innovative cancer care solutions.” – Cari-Anne Quinn, CEO, Life Sciences Hub Wales.
Improving Outcomes Through Screening Awareness
Of course, while the new tech solutions are groundbreaking, another award-winning Welsh project is saving lives from Cancer through raising awareness of the importance of screening.
Welsh Cancer Survivor, campaigner, and Award Winning HR Consultant Julie Grabham said:
“Wales is at the forefront of cancer technology, with a number of really projects which will vastly improve outcomes for patients. I have learned so much about the research taking place in Wales since my own diagnosis and it has made me even prouder to be based here. However, there is also progress to be made through simple measures like improving access to screening – as not all employees are able to get time off work to attend screening appointments.
“The JGHR Pledge is a project I started to help employers save more lives through supporting screening appointments. A routine appointment saved my life.”
“I’m asking employers to sign the JGHR pledge and give their staff paid leave to attend screenings. I also work with cancer charities to help employers learn how to best support employees with cancer in the workplace.”
It’s estimated that 1300 lives are saved each year through screening for breast cancer alone – including Julie’s. Now, thanks to Julie’s work, over 160 businesses have already committed to give employees paid time off for cancer screening appointments – saving even more.
Wales is open for business, and Life Sciences Wales is encouraging industry partners with innovative solutions to cancer care to join them in the fight against cancer.
Submit your innovations here: Innovation enquiry form | Life Sciences (lshubwales.com)
